May 10, 2022
Biomind Labs At PSYCH Symposium Biomind Labs announced it was relocating from Toronto to Cambridge, recognising the opportunities in Europe’s
May 4, 2022
Negev Capital With US$30 million under its management, Negev Capital is a fund focused on psychedelic drug development, with investments
April 27, 2022
At the start of 2022, the FDA cleared MindMed’s Investigational New Drug (IND) application for MM-120, paving the way for
April 6, 2022
Psilocybin was first isolated in 1958 by Albert Hofmann and is one of the most researched psychedelic medicines, with over
March 16, 2022
At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across
